Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

Section 32

Founders Bill Maris

Overview

Investments

Unlock datapoints

Portfolio analytics

Team

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.

Need help with fundraising?

We offer an assisted fundraising option for startups

Learn more
Total investments 117
Average round size
info
The average size of a deal this fund participated in
$66M
Portfolio companies 79
Rounds per year 16.71
Lead investments 9
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.32
Exits 6
Key employees 2

Areas of investment

  • Health Care
  • Biotechnology
  • Artificial Intelligence
  • Medical
  • Therapeutics
Summary

In 2017 was created Section 32, which is appeared as VC. The leading representative office of defined VC is situated in the San Diego. The company was established in North America in United States.

Among the most popular portfolio startups of the fund, we may highlight Coinbase, Auris Health, Inc., Lime. The fund has no specific favorite in a number of founders of portfolio startups. In case when startup counts 5+ of the founder, the chance for it to get the investment is meager. Among the most popular fund investment industries, there are Software, Medical. Besides, a startup needs to be aged 4-5 years to get the investment from the fund. For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States.

The usual cause for the fund is to invest in rounds with 6-7 partakers. Despite the Section 32, startups are often financed by Founders Fund, Polaris Partners, Lux Capital. The meaningful sponsors for the fund in investment in the same round are Andreessen Horowitz, Verily, GV. In the next rounds fund is usually obtained by Andreessen Horowitz, GV, Y Combinator.

The fund was created by Bill Maris. We also calculated 2 valuable employees in our database.

Opposing the other organizations, this Section 32 works on 20 percentage points less the average amount of lead investments. The increased amount of exits for fund were in 2019. The common things for fund are deals in the range of 50 - 100 millions dollars. When the investment is from Section 32 the average startup value is 500 millions - 1 billion dollars. The fund is generally included in 7-12 deals every year. The top activity for fund was in 2019. Considering the real fund results, this VC is 7 percentage points less often commits exit comparing to other organizations.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of Section 32:
Typical Co-investors
Section 32 is more likely to invest in rounds together with the following funds:
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after Section 32:

Look at other 50 related and similar funds Collapse list
Fund NameLocation
AAJ Capital LLC -
Angel Capital Management Italy, Lombardy, Milan
Charoen Pokphand Foods PCL Bangkok, Krung Thep, Thailand
Charter School Growth Fund Broomfield, Colorado, United States
Electra Invest -
Frontrow Energy Technology Aberdeen City, Dyce, United Kingdom
Gordon and Betty Moore Foundation California, Palo Alto, United States
Hivos-Triodos Fund -
KBC Japan Fukuoka, Fukuoka Prefecture, Japan
Meriton Capital -
New India Investment Corporation Canada, Ontario, Toronto
Newcrest Mining Australia, Melbourne, Victoria
Rongze Ziben China, Guangdong, Shenzhen
Sapphire Lake Investment Beijing, Beijing, China
Shanghai Wuqi Touzi China, Shanghai
Shanghai Zhixuan Chuangtou China, Shanghai
Sparkling StarCapital Beijing, Beijing, China
The Oil & Gas Technology Centre Aberdeen, Scotland, United Kingdom
Viola Partners Herzliya, Israel, Tel Aviv
Zhuojia Huizhi Chuangtou China, Guangdong, Shenzhen

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Pomelo

Financial Services
FinTech
Information Technology
$40M17 Jan 2024 Entre Ríos Province, Argentina

ROME Therapeutics

Biotechnology
Health Care
Pharmaceutical
$72M12 Sep 2023 Cambridge, Massachusetts, United States

Inceptive

Biotechnology
Life Science
Medical
$100M07 Sep 2023 Palo Alto, California, United States

Endor Labs

Security
Software
$70M03 Aug 2023 -

Octave Bioscience

Biotechnology
Clinical Trials
Health Care
Health Diagnostics
Medical
$32M26 Jul 2023 California, United States

AltPep

Biotechnology
$52M22 Jun 2023 Washington, United States

Delve Bio

Biotechnology
Health Care
$35M20 Jun 2023 San Francisco, California, United States

Function Oncology

Biotechnology
Genetics
Therapeutics
$28M12 Apr 2023 San Diego, California, United States

Faro Health

Health Care
Software
$20M08 Feb 2023 La Jolla, California, United States
News
ROME Therapeutics Secures $77 Million in Series B Financing to Advance Repeatome-derived Pipeline for Cancer and Autoimmune Diseases and Expand Repeatomics Platform

– ROME Therapeutics announced the completion of a $77m Series B financing round.
– The round was led by new investor Section 32 and included participation from Sanofi Ventures, Casdin Capital, Andreessen Horowitz and Alexandria Venture Investments.
– ROME’s mission is to harness the power of the repeatome – the roughly 60% of the human genome consisting of repetitive sequences of nucleic acids, known as repeats – to discover powerful new classes of medicines for cancer and autoimmune diseases.
– ROME has identified multiple repeatome-derived targets and created an internal data science platform, called repeatomics, to analyze vast quantities of data available through the repeatome.

Syllable Raises $28 Million Led by Oak HC/FT to Transform Customer Service in Healthcare

– Syllable announced a $28m Series B funding round to modernize customer service in healthcare.
– The round was led by Oak HC/FT with participation from previous investor Section 32 and will be utilized to scale partnerships with health systems, deploy with payers, and grow the team.
– Currently, most consumer-facing industries offer a digital-first customer service experience that relies primarily on self-service options. Healthcare is different, with eight out of nine people choosing to contact their healthcare provider on the phone. Yet, callers often face long call hold times, endless transfers and dead ends.

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Section 32?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!
Total investments 117
Average round size 66M
Rounds per year 16.71
Peak activity year 2021
Lead investments 9
Follow on index 0.32
Exits 6
Group Appearance index 0.97

Latest deals

CompanyIndustryRound SizeDateInvestorsLocation

Pomelo

Financial Services
FinTech
Information Technology
$40M17 Jan 2024 Entre Ríos Province, Argentina

ROME Therapeutics

Biotechnology
Health Care
Pharmaceutical
$72M12 Sep 2023 Cambridge, Massachusetts, United States

Inceptive

Biotechnology
Life Science
Medical
$100M07 Sep 2023 Palo Alto, California, United States

Endor Labs

Security
Software
$70M03 Aug 2023 -

Octave Bioscience

Biotechnology
Clinical Trials
Health Care
Health Diagnostics
Medical
$32M26 Jul 2023 California, United States

AltPep

Biotechnology
$52M22 Jun 2023 Washington, United States

Delve Bio

Biotechnology
Health Care
$35M20 Jun 2023 San Francisco, California, United States

Function Oncology

Biotechnology
Genetics
Therapeutics
$28M12 Apr 2023 San Diego, California, United States

Faro Health

Health Care
Software
$20M08 Feb 2023 La Jolla, California, United States
Crunchbase icon

Content report

The following text will be sent to our editors: